Atlanta, Georgia – October 14, 2021 – DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative health research, services, and solutions to federal agencies, today announced that it has been awarded a contract to provide experienced medical personnel to support COVID-19 community testing and collection, vaccination, and monoclonal antibody therapy throughout the state of Alaska. The award complements a separate contract to provide medical countermeasures and emergency medical support to Alaska as the state responds to an increase in COVID-19 cases, which DLH announced in mid-September.
This competitive award, procured under a Federal Emergency Management Agency (“FEMA”) contract to provide support for states seeking medical support during the COVID-19 pandemic, has a ceiling value of $20 million for the 90-day base period. It provides for three one-month optional extensions after the initial period of performance. As the prime contractor, DLH will provide the emergency medical logistics coordination for the healthcare team fielded by its subcontractor, which will be responsible for a significant percentage of the services rendered.
“DLH is proud of our expanding relationship with the state of Alaska, and we are well prepared for this opportunity to provide additional COVID-19 response support activities,” said Kevin Wilson, president of DLH’s Health & Logistics Services operating unit. “Vaccination, testing, and monoclonal antibody treatment are key tools in the battle against this pandemic, and our team will work swiftly to ensure the skilled staff are in place to provide Alaskans with these vital countermeasures.”
Under this contract, DLH will continue to leverage its relationship with a nationally recognized temporary medical staffing firm to place experienced support personnel in communities throughout the state. These healthcare professionals will augment the existing staff already providing emergency medical support services in Alaska.
“Our company continues to utilize its healthcare delivery expertise in support of the national response to COVID-19,” added Zach Parker, President and CEO of DLH. “Ensuring the efficient distribution and safe administration of medical countermeasures such as testing, vaccination and therapeutics during public health emergencies is vitally important, and DLH will draw upon its relevant experience to deliver results for the people of Alaska.”
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding estimates of future revenues, operating income, earnings and cash flow. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this release due to a variety of factors, including: the outbreak of the novel coronavirus (“COVID-19”), including the measures to reduce its spread, and its impact on the economy and demand for our services, are uncertain, cannot be predicted, and may precipitate or exacerbate other risks and uncertainties; the risk that we will not realize the anticipated benefits of our recent or any future acquisition; the challenges of managing larger and more widespread operations resulting from our recent acquisition; contract awards in connection with re-competes for present business and/or competition for new business; compliance with new bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the ability to successfully integrate the operations our recent acquisition and of any future acquisitions; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2020, as well as subsequent reports filed thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.
INVESTOR RELATIONS CONTACT:
Contact: Chris Witty